{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:05:22Z","timestamp":1761609922145,"version":"build-2065373602"},"reference-count":80,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.revmed.2016.10.390","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T09:46:11Z","timestamp":1479721571000},"page":"312-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prise en charge des \u00e9v\u00e9nements ind\u00e9sirables chez les patients sous traitement par immunoglobulines\u00a0: recommandations pour la pratique clinique"],"prefix":"10.1016","volume":"38","author":[{"given":"I.","family":"Marie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ch\u00e9rin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Pelus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dantal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Crave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Delain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-F.","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.revmed.2016.10.390_bib0005","first-page":"79","article-title":"Side effects of intravenous immune globulins","volume":"97","author":"Duhem","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.10.390_bib0015","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gamma globulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2016.10.390_bib0020","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1006\/clim.2001.5132","article-title":"Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency","volume":"101","author":"Razvi","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0030","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","article-title":"Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines","volume":"22","author":"Dalakas","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.revmed.2016.10.390_bib0035","first-page":"139","article-title":"Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases","volume":"19","author":"Dashti-Khavidaki","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0040","first-page":"13","article-title":"The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases\u00a0\u2013\u00a02008","volume":"10","author":"Shoenfeld","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.revmed.2016.10.390_bib0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12026-007-0003-5","article-title":"Safety of IGIV therapy and infusion-related adverse events","volume":"38","author":"Ballow","year":"2007","journal-title":"Immunol Res"},{"key":"10.1016\/j.revmed.2016.10.390_bib0050","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2215\/CJN.01701105","article-title":"Safety and adverse events profiles of intravenous gamma globulin products used for immunomodulation: a single-center experience","volume":"1","author":"Vo","year":"2006","journal-title":"CJASN"},{"key":"10.1016\/j.revmed.2016.10.390_bib0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0060","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2016.10.390_bib0065","first-page":"157","article-title":"Intravenous administration of human \u03b3-globulin","volume":"7","author":"Barandun","year":"1962","journal-title":"Vox Sang"},{"key":"10.1016\/j.revmed.2016.10.390_bib0070","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1537-2995.2003.00519.x","article-title":"Intravenous immune globulins: an update for clinicians","volume":"43","author":"Knezevic-Maramica","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.revmed.2016.10.390_bib0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-199921030-00003","article-title":"Adverse effects of intravenous immunoglobulin therapy","volume":"21","author":"Nydegger","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.revmed.2016.10.390_bib0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1423-0410.1998.7420074.x","article-title":"IVIG adverse reactions: potential role of cytokines and vasoactive substances","volume":"74","author":"Bagdasarian","year":"1998","journal-title":"Vox Sang"},{"key":"10.1016\/j.revmed.2016.10.390_bib0090","series-title":"Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey","first-page":"1","author":"IDF","year":"2003"},{"key":"10.1016\/j.revmed.2016.10.390_bib0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1423-0410.2012.01596.x","article-title":"Measures to prevent transfusion-related acute lung injury (TRALI)","volume":"103","author":"Reesink","year":"2012","journal-title":"Vox sanguinis"},{"key":"10.1016\/j.revmed.2016.10.390_bib0100","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta-analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2015.12.003","article-title":"Long-term subcutaneous immunoglobulin use in inflammatory myopathies: a retrospective review of 19 cases","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0115","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/pds.1449","article-title":"Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study","volume":"16","author":"Debes","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.revmed.2016.10.390_bib0120","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/ijd.12802","article-title":"Biologics in dermatology: adverse effects","volume":"54","author":"Sehgal","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.aller.2014.05.005","article-title":"IgG anti-IgA antibodies in paediatric antibody-deficient patients receiving intravenous immunoglobulin","volume":"43","author":"Torabi Sagvand","year":"2015","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.revmed.2016.10.390_bib0130","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","article-title":"The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature","volume":"129","author":"Rachid","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00915353","article-title":"Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin","volume":"3","author":"Welch","year":"1983","journal-title":"J Clin Immunol"},{"issue":"Suppl. 15","key":"10.1016\/j.revmed.2016.10.390_bib0140","first-page":"S53","article-title":"Safety and side effects of IV immunoglobulin therapy","volume":"14","author":"Nydegger","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.patbio.2004.06.001","article-title":"[Transfusion-related acute lung injury (TRALI): an unrecognised pathology]","volume":"53","author":"Moalic","year":"2005","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.revmed.2016.10.390_bib0150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/eci.10.104","article-title":"Indications and safety of intravenous and subcutaneous immunoglobulin therapy","volume":"7","author":"Rezaei","year":"2011","journal-title":"Exp Rev Clin Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies\u00a0\u2013\u00a0a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0160","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0165","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/WNL.59.12_suppl_6.S33","article-title":"Intravenous gamma globulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies","volume":"59","author":"Brannagan","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2016.10.390_bib0170","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2016.10.390_bib0175","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.intimp.2005.11.015","article-title":"Adverse events associated with intravenous immunoglobulin therapy","volume":"6","author":"Hamrock","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0180","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1526-4610.1998.3804317.x","article-title":"Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications","volume":"38","author":"Finkel","year":"1998","journal-title":"Headache"},{"key":"10.1016\/j.revmed.2016.10.390_bib0185","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJM199308193290820","article-title":"Recurrent migraine and intravenous immune globulin therapy","volume":"329","author":"Constantinescu","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.10.390_bib0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1546-0096-9-28","article-title":"Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease","volume":"9","author":"Kemmotsu","year":"2011","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.revmed.2016.10.390_bib0195","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/trf.13200","article-title":"Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center","volume":"55","author":"Bharath","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.revmed.2016.10.390_bib0200","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14740338.4.2.285","article-title":"Drug-induced aseptic meningitis","volume":"4","author":"Hopkins","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.revmed.2016.10.390_bib0205","first-page":"2311","article-title":"Acute encephalopathy associated with intravenous immunoglobulin therapy","volume":"26","author":"Wada","year":"2005","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0210","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00043426-199911000-00012","article-title":"Corticosteroid prophylaxis for neurologic complications of intravenous immunoglobulin G therapy in childhood immune thrombocytopenic purpura","volume":"21","author":"Jayabose","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0220","first-page":"518","article-title":"Renal insufficiency and failure associated with immune globulin intravenous therapy\u00a0\u2013\u00a0United States, 1985\u20131998","volume":"48","author":"Centers for Disease Control, Prevention (CDC)","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.revmed.2016.10.390_bib0225","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/qjmed\/93.11.751","article-title":"Nephrotoxicity of intravenous immunoglobulin","volume":"93","author":"Levy","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.revmed.2016.10.390_bib0230","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1592\/phco.2005.25.6.886","article-title":"Intravenous immunoglobulin-associated acute renal failure: case series and literature review","volume":"25","author":"Itkin","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.revmed.2016.10.390_bib0235","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.semarthrit.2004.06.003","article-title":"Intravenous immunoglobulin and the kidney\u00a0\u2013\u00a0a two-edged sword","volume":"34","author":"Orbach","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.10.390_bib0240","first-page":"60","article-title":"Important drug warning: immune globulin intravenous (human) (IGIV) products","volume":"19","author":"Epstein","year":"2000","journal-title":"Neonatal Netw"},{"key":"10.1016\/j.revmed.2016.10.390_bib0245","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000354893","article-title":"Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk","volume":"38","author":"Dantal","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0250","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/pds.2273","article-title":"Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose containing intravenous immunoglobulins. A case-control study","volume":"21","author":"Onuigbo","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.revmed.2016.10.390_bib0255","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/pds.2253","article-title":"Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose containing intravenous immunoglobulins: a case-control study","volume":"21","author":"Moulis","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.revmed.2016.10.390_bib0260","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1160\/TH06-09-0503","article-title":"Intravenous immunoglobulin-associated vena cava thrombosis","volume":"96","author":"Marie","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.revmed.2016.10.390_bib0265","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0270","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1212\/WNL.59.12_suppl_6.S28","article-title":"Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy","volume":"59","author":"Lemm","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2016.10.390_bib0275","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00120-015-3941-x","article-title":"Segmental testicular infarction. Unusual complication of intravenous immunoglobulin therapy for multifocal motor neuropathy","volume":"54","author":"R\u00fcb","year":"2015","journal-title":"Urologe A"},{"key":"10.1016\/j.revmed.2016.10.390_bib0280","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1440-1797.2010.01399.x","article-title":"Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection","volume":"16","author":"Huang","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.revmed.2016.10.390_bib0285","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2230.2008.02809.x","article-title":"Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases","volume":"34","author":"Mignogna","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0290","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1537-2995.2008.01721.x","article-title":"Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis","volume":"48","author":"Daw","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.revmed.2016.10.390_bib0295","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/s10165-004-0316-3","article-title":"An infant with gamma globulin-induced hypersensitivity syndrome who developed Evans\u2019 syndrome after a second gamma globulin treatment","volume":"14","author":"Miyamae","year":"2004","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0300","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/(SICI)1096-8652(200003)63:3<160::AID-AJH11>3.0.CO;2-4","article-title":"Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease","volume":"63","author":"Nakagawa","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0305","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1546-0096-10-10","article-title":"Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases","volume":"10","author":"Berard","year":"2012","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.revmed.2016.10.390_bib0310","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2215\/CJN.04540709","article-title":"Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients","volume":"4","author":"Kahwaji","year":"2009","journal-title":"CJASN"},{"key":"10.1016\/j.revmed.2016.10.390_bib0315","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1399-3038.2009.00885.x","article-title":"Intravenous immunoglobulin-induced neutropenia","volume":"21","author":"Khan","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0320","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1399-3038.2008.00741.x","article-title":"Neutropenia in antibody-deficient patients under IVIG replacement therapy","volume":"20","author":"Lemos","year":"2009","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0325","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0192-0561(99)00020-X","article-title":"Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming","volume":"21","author":"Berkovitch","year":"1999","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0330","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.mph.0000155871.26380.84","article-title":"Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia","volume":"27","author":"Niebanck","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0335","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0165-5728(95)00167-0","article-title":"Neutropenia in a patient receiving intravenous immune globulin","volume":"64","author":"Tam","year":"1996","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0340","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood-2006-05-021568","article-title":"Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations","volume":"108","author":"von Gunten","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2016.10.390_bib0345","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00002826-200311000-00009","article-title":"Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders","volume":"26","author":"Matsuda","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0350","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2165\/00128071-200708050-00004","article-title":"Variations in serum hemoglobin, albumin, and electrolytes in patients receiving intravenous immunoglobulin therapy: a real clinical threat?","volume":"8","author":"Mignogna","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0355","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10157-006-0416-9","article-title":"True hyponatremia secondary to intravenous immunoglobulin","volume":"10","author":"Nguyen","year":"2006","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0360","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/096120339900800617","article-title":"Intravenous immunoglobulin infusion causing pseudohyponatremia","volume":"8","author":"Ng","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2016.10.390_bib0365","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.10325","article-title":"Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia","volume":"73","author":"Steinberger","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2016.10.390_bib0370","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.autrev.2014.08.023","article-title":"Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study","volume":"13","author":"Danieli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0375","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.autrev.2015.11.010","article-title":"Kawasaki disease in adults: observations in France and literature review","volume":"15","author":"Fraison","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0380","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2015.04.002","article-title":"Kawasaki disease: an evolving paradigm","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0385","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.autrev.2015.03.005","article-title":"Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature","volume":"14","author":"Guidelli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0390","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.autrev.2015.04.003","article-title":"The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis","volume":"14","author":"Katz-Agranov","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0395","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.autrev.2015.01.005","article-title":"The effect of a triple therapy on maternal anti-Ro\/SS-A levels associated to fetal cardiac manifestations","volume":"14","author":"Mart\u00ednez-S\u00e1nchez","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.10.390_bib0400","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.autrev.2015.11.009","article-title":"Intravenous immunoglobulins and antiphospholipid syndrome: how, when and why? A review of the literature","volume":"15","author":"Tenti","year":"2016","journal-title":"Autoimmun Rev"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866316309717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866316309717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:37:27Z","timestamp":1759336647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866316309717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0248866316309717"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2016.10.390","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge des \u00e9v\u00e9nements ind\u00e9sirables chez les patients sous traitement par immunoglobulines\u00a0: recommandations pour la pratique clinique","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2016.10.390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}